Literature DB >> 14983225

Enhancement of endogenous fibrinolysis does not reduce local fibrin deposition, but modulates inflammation upon intestinal ischemia and reperfusion.

Ivo G Schoots1, Marcel Levi, Arlène K van Vliet, Paul J Declerck, Adrie M Maas, Thomas M van Gulik.   

Abstract

This study investigated the contribution of endogenous suppression of fibrinolysis and increased fibrin deposition to intestinal dysfunction and injury in a rat model of intestinal ischemia/reperfusion (I/R), as fibrinolytic inhibition may lead to thrombotic obstructions that compromise microcirculation and promote intestinal injury. Circulatory fibrinolysis was enhanced by intravenous administration of recombinant tissue plasminogen activator (rt-PA) or by inhibition of PAI-I by administration of MA-33H1F7. Coagulation and fibrinolysis parameters obtained from portal blood were correlated to fibrin deposition (determined by anti-rat fibrin antibody staining), intestinal function (glucose/water clearance) and intestinal injury (histological evaluation by Park/Chiu score). Enhanced circulatory fibrinolytic activity, as evidenced by increased portal plasma plasminogen activator activity, elevated fibrin degradation products and decreased levels of PAI-I, did not reduce mucosal fibrin deposition and microthrombosis in postischemic intestinal tissue. Furthermore, rt-PA or anti-PAI-I antibody administration did not attenuate I/R-induced intestinal injury or dysfunction, as demonstrated by intestinal histopathology scores of 4.8+/-0.2 and 4.7+/-0.3 (control I/R group 4.7+/-0.2) and glucose clearances of 47+/-6 and 46+/-9 micro L/min g (control I/R group 30+/-8 micro L/min. g) after 40 minutes of intestinal ischemia and 3 hours of reperfusion, respectively. However, both interventions resulted in decreased levels of interleukin-6, which may indicate fibrin-induced modulation of inflammation. Attempts to enhance the fibrinolytic activity (either by rt-PA or by anti-PAI-I administration), indicated by increased portal plasma levels of released FDP, failed to decrease mucosal fibrin deposition and to attenuate intestinal I/R injury. Based on our observations and previous reports, the contribution of suppressed endogenous fibrinolysis to microcirculatory fibrin deposition and I/R-injury may be of limited importance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14983225     DOI: 10.1160/TH03-08-0529

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Effect of Reteplase and PAI-1 antibodies on postoperative adhesion formation in a laparoscopic mouse model.

Authors:  Maria Mercedes Binda; Bart W J Hellebrekers; Paul J Declerck; Philippe Robert Koninckx
Journal:  Surg Endosc       Date:  2008-09-24       Impact factor: 4.584

2.  Holothurian glycosaminoglycan inhibits metastasis and thrombosis via targeting of nuclear factor-κB/tissue factor/Factor Xa pathway in melanoma B16F10 cells.

Authors:  Yang Zhao; Daohai Zhang; Sheng Wang; Li Tao; Aiyun Wang; Wenxing Chen; Zhijie Zhu; Shizhong Zheng; Xiang Gao; Yin Lu
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

3.  Ischaemia-reperfusion injury impairs tissue plasminogen activator release in man.

Authors:  Christian M Pedersen; Gareth Barnes; Michael R Schmidt; Hans Erik Bøtker; Rajesh K Kharbanda; David E Newby; Nicholas L Cruden
Journal:  Eur Heart J       Date:  2011-10-11       Impact factor: 29.983

4.  Superior mesenteric vein thrombosis as an early presentation of myelodysplastic syndrome: a case report.

Authors:  Min Jung Kim; Hyun Joo Song; Woo Kun Kim; Sun Hyung Kim
Journal:  Intest Res       Date:  2014-04-29

5.  Nebulized fibrinolytic agents improve pulmonary fibrinolysis but not inflammation in rat models of direct and indirect acute lung injury.

Authors:  Jorrit J Hofstra; Alexander D Cornet; Paul J Declerck; Barry Dixon; Hamid Aslami; Alexander P J Vlaar; Joris J Roelofs; Tom van der Poll; Marcel Levi; Marcus J Schultz
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.